NT-101 not checked

NexThera Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“NT-101 is a topical ophthalmic solution containing pigment epithelium-derived factor (PEDF) 34 and type I atelocollagen”In the company’s words, NCT07811726 on ClinicalTrials.gov
Tested for
Wet Age Related Macular Degeneration
Main trialPhase 2
“This phase 2 trial is a randomized, double-blind, placebo-controlled, multicenter study in patients with wet AMD to assess the efficacy and safety of NT-101 topical ophthalmic solution (0.20 mM) administered into the study eye twice daily (BID) for 12 weeks.”In the company’s words, NCT07811726 on ClinicalTrials.gov

Other drugs for Wet Age Related Macular Degeneration

All 56 drugs for Wet Age Related Macular Degeneration

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 28 Feb 2028 A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
Phase 1/2Completed 15 Dec 2025 NT-101 Topical Ophthalmic Solution in Patients With Wet AMD
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow NT-101

Following is part of Solo: you see every change to NT-101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in